Coming therapies: adefovir.
Adefovir dipivoxil, an acyclic nucleotide phosphonate analogue, demonstrates a potent and sustained antiviral activity. Its long half-life allows once daily administration and due to the observed reduction in L-carnitine plasma levels, supplementation with L-carnitine is required. Clinical evidence indicates adefovir dipivoxil can be used as first-line therapy. In addition, due to the sensitivity of drug resistant strains to adefovir dipivoxil, it also has a role in second-line or multi-drug salvage regimens. Adefovir dipivoxil is safe and well tolerated for only short periods of treatment.
Angarano
G
G
University of Bari, Italy.
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D018432:Drug Resistance, Multiple; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
D000998:Antiviral Agents; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000225:Adenine; C106812:adefovir dipivoxil